Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma

BACKGROUND: High-dose melphalan (200 mg/m(2)) with autologous stem cell transplantation (ASCT) is the standard treatment for young patients with multiple myeloma (MM). However, the response rates after ASCT are often unsatisfactory. We performed a pilot study by using bortezomib-melphalan as conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Se Ryeon, Kim, Seok Jin, Park, Yong, Sung, Hwa Jung, Choi, Chul Won, Kim, Byung Soo
Formato: Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983035/
https://www.ncbi.nlm.nih.gov/pubmed/21120207
http://dx.doi.org/10.5045/kjh.2010.45.3.183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983035/
https://www.ncbi.nlm.nih.gov/pubmed/21120207
http://dx.doi.org/10.5045/kjh.2010.45.3.183

Ejemplares similares